Korro reports full year 2023 financial results and highlights recent progress

Cambridge, mass., march 26, 2024 (globe newswire) -- korro bio, inc. (korro) (nasdaq: krro), a biopharmaceutical company focused on developing a new class of genetic medicines for both rare and highly prevalent diseases, today reported financial results for the full year ended december 31, 2023, and reiterated its recent progress and anticipated milestones.

KRRO Ratings Summary

KRRO Quant Ranking